These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30369062)

  • 21. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
    Berg K; Roald AB; Navaratnam J; Bragadóttir R
    Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
    Ying GS; Maguire MG; Daniel E; Ferris FL; Jaffe GJ; Grunwald JE; Toth CA; Huang J; Martin DF;
    Ophthalmology; 2015 Dec; 122(12):2523-31.e1. PubMed ID: 26383996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
    Ramakrishnan MS; Yu Y; VanderBeek BL
    JAMA Ophthalmol; 2020 Mar; 138(3):237-242. PubMed ID: 32027349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results.
    Michalewski J; Nawrocki J; Izdebski B; Michalewska Z
    Indian J Ophthalmol; 2014 May; 62(5):554-60. PubMed ID: 24881600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
    Frenkel RE; Shapiro H; Stoilov I
    Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Daniel E; Ying GS; Kim BJ; Toth CA; Ferris F; Martin DF; Grunwald JE; Jaffe GJ; Dunaief JL; Pan W; Maguire MG;
    Ophthalmology; 2019 May; 126(5):743-751. PubMed ID: 30476517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
    Rush RB; Rush SW; Aragon AV; Ysasaga JE
    Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
    Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
    Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scheduled versus Pro Re Nata Dosing in the VIEW Trials.
    Richard G; Monés J; Wolf S; Korobelnik JF; Guymer R; Goldstein M; Norenberg C; Sandbrink R; Zeitz O
    Ophthalmology; 2015 Dec; 122(12):2497-503. PubMed ID: 26477840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration.
    Nunes RP; Hirai FE; Barroso LF; Badaró E; Novais E; Rodrigues EB; Maia M; Magalhães O; Farah ME
    Arq Bras Oftalmol; 2019; 82(3):225-232. PubMed ID: 30810619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.